137 related articles for article (PubMed ID: 35267592)
1. Molecular Landscape of Small Bowel Adenocarcinoma.
Pandya K; Overman MJ; Gulhati P
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267592
[TBL] [Abstract][Full Text] [Related]
2. Genomic Profiling of Small-Bowel Adenocarcinoma.
Schrock AB; Devoe CE; McWilliams R; Sun J; Aparicio T; Stephens PJ; Ross JS; Wilson R; Miller VA; Ali SM; Overman MJ
JAMA Oncol; 2017 Nov; 3(11):1546-1553. PubMed ID: 28617917
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma.
Pan H; Cheng H; Wang H; Ge W; Yuan M; Jiang S; Wan X; Dong Y; Liu Z; Zhao R; Fang Y; Lou F; Cao S; Han W
Cancer Sci; 2021 Nov; 112(11):4758-4771. PubMed ID: 34449929
[TBL] [Abstract][Full Text] [Related]
4. The evolving management of small bowel adenocarcinoma.
de Bree E; Rovers KP; Stamatiou D; Souglakos J; Michelakis D; de Hingh IH
Acta Oncol; 2018 Jun; 57(6):712-722. PubMed ID: 29381126
[TBL] [Abstract][Full Text] [Related]
5. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
6. Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management.
Gelsomino F; Balsano R; De Lorenzo S; Garajová I
Curr Oncol; 2022 Feb; 29(2):1223-1236. PubMed ID: 35200603
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive genomic profiling of small bowel adenocarcinoma by tissue and plasma biopsy.
Yu D; Wang J; Zheng B; Yuan M; Gu D; Chen R; Chen X
Genomics; 2024 Jan; 116(1):110766. PubMed ID: 38141930
[TBL] [Abstract][Full Text] [Related]
8. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.
Laforest A; Aparicio T; Zaanan A; Silva FP; Didelot A; Desbeaux A; Le Corre D; Benhaim L; Pallier K; Aust D; Pistorius S; Blons H; Svrcek M; Laurent-Puig P
Eur J Cancer; 2014 Jul; 50(10):1740-1746. PubMed ID: 24797764
[TBL] [Abstract][Full Text] [Related]
9. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
[TBL] [Abstract][Full Text] [Related]
11. Small bowel adenocarcinoma: An overview.
Khosla D; Dey T; Madan R; Gupta R; Goyal S; Kumar N; Kapoor R
World J Gastrointest Oncol; 2022 Feb; 14(2):413-422. PubMed ID: 35317322
[TBL] [Abstract][Full Text] [Related]
12. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
[TBL] [Abstract][Full Text] [Related]
13. Genomic Profiling Reveals the Molecular Landscape of Gastrointestinal Tract Cancers in Chinese Patients.
Zhu C; Zhu L; Gu Y; Liu P; Tong X; Wu G; Zhu W; Shen W; Bao H; Ma X; Yu R; Wu X; Zhu D; Shu Y; Feng J
Front Genet; 2021; 12():608742. PubMed ID: 34594355
[TBL] [Abstract][Full Text] [Related]
14. Exome-wide somatic mutation characterization of small bowel adenocarcinoma.
Hänninen UA; Katainen R; Tanskanen T; Plaketti RM; Laine R; Hamberg J; Ristimäki A; Pukkala E; Taipale M; Mecklin JP; Forsström LM; Pitkänen E; Palin K; Välimäki N; Mäkinen N; Aaltonen LA
PLoS Genet; 2018 Mar; 14(3):e1007200. PubMed ID: 29522538
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.
Gulhati P; Raghav K; Shroff R; Varadhachary G; Javle M; Qiao W; Wang H; Morris J; Wolff R; Overman MJ
Oncologist; 2018 Mar; 23(3):277-e26. PubMed ID: 29259073
[TBL] [Abstract][Full Text] [Related]
16. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study.
Aparicio T; Svrcek M; Zaanan A; Beohou E; Laforest A; Afchain P; Mitry E; Taieb J; Di Fiore F; Gornet JM; Thirot-Bidault A; Sobhani I; Malka D; Lecomte T; Locher C; Bonnetain F; Laurent-Puig P
Br J Cancer; 2013 Dec; 109(12):3057-66. PubMed ID: 24196786
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Molecular Features and Treatment Options for Small Bowel Adenocarcinoma.
Cordova-Delgado M; Pizarro G; Pinto MP; Herrera ME; Garrido M
Front Oncol; 2021; 11():593561. PubMed ID: 33777741
[TBL] [Abstract][Full Text] [Related]
18. Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?
Casadei-Gardini A; Lonardi S; Smiroldo V; Canale M; Passardi A; Silvestris N; Orsi G; Nappo F; Rimassa L; Fassan M; Spaggiari P; Brunetti O; Andrikou K; Cascinu S
Med Oncol; 2021 Feb; 38(2):17. PubMed ID: 33528694
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
20. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
